Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High-grade Astrocytoma NOS Clear all
Active, not recruiting Not applicable Interventional

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03739372
View directory record Official record
Conditions
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions
Specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

NCT03020602
View directory record Official record
Conditions
Gliosarcoma, Recurrent Glioblastoma, Astrocytoma of Brain, Glioblastoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Ubidecarenone Injectable Nanosuspension
Other · Drug
Lead sponsor
Seema Nagpal
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

NCT00667394
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Jul 23, 2026, 2:43 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

NCT07389278
View directory record Official record
Conditions
Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Hemispheric Glioma, H3G34 Mutant
Interventions
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 39 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

NCT00052780
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
O6-benzylguanine, temozolomide, filgrastim, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

NCT01403610
View directory record Official record
Conditions
HIGH GRADE GLIOMA
Interventions
TH-302 preoperative, Placebo, TH-302 (escalating) with bevacizumab 10mg/kg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 23, 2026, 2:43 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

NCT00683761
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
Interventions
131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2009 · Synced Jul 23, 2026, 2:43 AM EDT
Withdrawn Phase 1 Interventional

A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma

NCT06501911
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent High-grade Glioma
Interventions
Bicalutamide, Intensity-modulated radiation therapy (IMRT)
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma

NCT00357253
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
capecitabine, radiation therapy
Drug · Radiation
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

NCT02859857
View directory record Official record
Conditions
Neoplasms
Interventions
BXQ-350
Drug
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Lexington, Kentucky • Albuquerque, New Mexico • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas

NCT01653834
View directory record Official record
Conditions
Glioblastoma
Interventions
Lymphocyte harvesting & reinfusion
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated Phase 2 Interventional Results available

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

NCT01836549
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors
Interventions
imetelstat sodium
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
12 Months to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma

NCT00720564
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional

Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

NCT02722512
View directory record Official record
Conditions
Glioblastoma Multiforme, Astrocytoma, Grade III, Anaplastic Ependymoma, Clear Cell Ependymoma, Ependymoma
Interventions
Heat Shock Protein Peptide Complex-96 (HSPPC-96), Tumor Resection, Radiation
Biological · Procedure · Radiation
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
3 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

NCT02101905
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
Interventions
Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate, Pharmacological Study, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jul 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 4 Interventional

Pediatric Long-Term Follow-up and Rollover Study

NCT03975829
View directory record Official record
Conditions
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
Interventions
dabrafenib, trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 99 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Terminated No phase listed Observational

Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors

NCT05934630
View directory record Official record
Conditions
Anaplastic Astrocytoma, Diffuse Brainstem Glioma, Glioblastoma Multiforme, High-grade Astrocytoma NOS, Fibrillary Astrocytoma, Low-Grade Astrocytoma, Nos, Pilocytic Astrocytoma, Choroid Plexus Carcinoma, CNS Primary Tumor, Nos, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, Ependymoma, NOS, Anaplastic Oligodendroglioma, Oligodendroglioma, Nos, CNS Germ Cell Tumor, Pineoblastoma, Diffuse Leptomeningeal Glioneuronal Tumor
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 40 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 1 Interventional

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

NCT07031765
View directory record Official record
Conditions
Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Ependymoma, Grade IV Astrocytoma
Interventions
exHSC, Nivolumab, Resection or biopsy
Biological · Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 26 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 2:43 AM EDT
Recruiting Phase 1 Interventional

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT04573140
View directory record Official record
Conditions
Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

NCT07301268
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Astrocytoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pembrolizumab, Surgical Procedure
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

NCT00002485
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
26
States / cities
Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas

NCT00075894
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
L-alanosine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2009 · Synced Jul 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

NCT05561374
View directory record Official record
Conditions
High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
Interventions
Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID, High-dose OKN-007, TID
Drug
Lead sponsor
Oblato, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Santa Monica, California • Louisville, Kentucky • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 23, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

NCT06264388
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma
Interventions
DB107-RRV, DB107-FC
Drug
Lead sponsor
Ashish Shah
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 23, 2026, 2:43 AM EDT